Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine.

Journal of viral hepatitis - 1 Jul 2003

Bozdayi A M, Uzunalimoğlu O, Türkyilmaz A R, Aslan N, Sezgin O, Sahin T, Bozdayi G, Cinar K, Pai S B, Pai R, Bozkaya H, Karayalçin S, Yurdaydin C, Schinazi R F

Abstract excerpt

The emergence of drug-resistant virus in hepatitis B virus (HBV) patients treated with lamivudine is well documented. In this study, we determined the mutations occurring in the tyrosine-methionine-aspartate-aspartate (YMDD) amino acid motif of the HBV DNA polymerase gene, as well as upstream and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA-Directed DNA Polymerase
Share to Drug Resistance, Viral
Share to Gene Products, pol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Share to Pharmacogenetics

Share to Reference Values

Source

Identifiers

PMID: 12823591
DOI: 10.1046/j.1365-2893.2003.00435.x

Genes

AGT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12823591-2026-09-02.1. Manifest publication-graph-cohort-2026-09-02.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine.PMID 12823591Read ↗

Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy.Semantic proximity Read ↗

Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.Semantic proximity Read ↗

rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.Semantic proximity Read ↗

Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.Semantic proximity Read ↗

Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.Semantic proximity Read ↗

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.Semantic proximity Read ↗

Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.Semantic proximity Read ↗

Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.Semantic proximity Read ↗

Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.Semantic proximity Read ↗

[Clinical and virologic characteristics of lamivudine resistance in HBV-associated chronic liver disease].Semantic proximity Read ↗

Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.Semantic proximity Read ↗

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.